Bullfrog AI Holdings, Inc. (BFRG) - Narxning foydaga nisbati

Bullfrog AI - BFRG emitenti grafik logotipi

Bullfrog AI Holdings (BFRG) rahbariyati farmatsevtika ishlab chiqish xarajatlarini minimallashtirish maqsadida istiqbolli dori vositasi nomzodlarini tezkor aniqlash uchun neyron tarmoqlarini joriy qilmoqda. Korxona hozirda molekulalarni sinovdan o'tkazishning erta bosqichlarini optimallashtirish uchun o'z IT yechimini kengaytirmoqda, ushbu bozor qiymati -1.80 indikatori aks etgan narxlar grafigi bilan tasdiqlanadi. Kompaniyaning o'sishi biodatalarni tahlil qilish uchun mo'ljallangan bfLeap tizimining kengayishi va yuqori marjali SaaS to'lovlarining ulushi ortishiga bog'liq.

Bullfrog AI Holdings (BFRG): Narxning foydaga nisbati 28.04.2023dan 12.11.2026gacha

Bullfrog AI Holdings, Inc. (BFRG) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- joriy narx va aksiyalarning prognoz qilingan qiymati:
Kompaniyaning har tomonlama tahlili:bullfrogai.com - BFRG
Bullfrog AI Holdings, Inc. brendining mahsuloti

Narx-foyda koeffitsiyenti bir dollar foydaning tannarxini belgilaydi, bu esa investorga aktiv uchun haddan tashqari to'lov darajasini yoki kapitalning stagnatsiya xavfini baholash imkonini beradi. Hisoblangan P/E multiplikatorini tahlil qilish orqali bozor joriy xarajatlarni Bullfrog AI Holdings (BFRG) kompaniyasining sun'iy intellektga asoslangan klinik ma'lumotlar tahlili sohasidagi salohiyati bilan solishtiradi, bunda yuqori baholash farmatsevtika sanoati uchun dori vositalarini ishlab chiqishni optimallashtirish bilan oqlanadi.

Raqobatdosh kompaniyalar tahlili

Narx-foyda multiplikatori VEEV (veeva.com)|P/E multiplikatori DOCS|Narxning foydaga nisbati HQY (HealthEquity Inc)|Waystar Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori CorVel Corp. CRVL|PRVA - Narxning foydaga nisbati|HURN: Narxning foydaga nisbati|Certara (CERT) - Narxning foydaga nisbati|OMCL (Omnicell Inc) - Narxning foydaga nisbati|GDRX (GoodRx Corp) - P/E multiplikatori|Schrodinger Corp - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Phreesia, Inc. (PHR)|OMDA (omadahealth.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Evolent Health EVH|HealthStream Inc (HSTM) - Kapitalizatsiyaning foydaga nisbati|Definitive Healthcare Inc. - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Consensus Corp (CCSI)|AGL (Agilon Health) - Narx-foyda koeffitsiyenti|absci.com - Kompaniya qiymatining sof foydaga nisbati|SY (So-Young International Inc.) - P/E multiplikatori|P/E multiplikatori National Research Corp|P/E multiplikatori SPOK|Biznesning o‘zini qoplash muddati OptimizeRx Inc.|TruBridge, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati SLP|SOPHiA GENETICS S.A. - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati HCAT (Health Catalyst Inc.)|carecloud.com (CCLD) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Research Solutions Inc. (RSSS)|Narxning foydaga nisbati DLH Corp|Narxning foydaga nisbati ONMD|P/E multiplikatori SCNX|Healthcare Triangle Inc - Narx-foyda multiplikatori|P/E multiplikatori ISPC (iSpecimen)|Biznesning o‘zini qoplash muddati SCWorx Inc (WORX)|MSPR - Narxning foydaga nisbati|ICCT (iCoreConnect Inc.) - Narx-foyda multiplikatori|MEDS: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Orgenesis Inc ORGS|Narxning foydaga nisbati R1 RCM, Inc.|Sharecare Inc (SHCR) - Biznesning o‘zini qoplash muddati|P/E multiplikatori STRM|Narxning foydaga nisbati SYRA (syrahealth.com)|P/E multiplikatori AMEH (Apollo Medical Holdings, Inc.)|MODN (Model N Inc) - Kapitalizatsiyaning sof foydaga nisbati|NXGN - Narxning foydaga nisbati